Mark A. Socinski, MD, AdventHealth Cancer Institute

Final takeaways from ASCO 2021 and the use of immunotherapy to treat various types of patients with non–small cell lung cancer.

The potential clinical utility of blood-based biomarkers in non–small cell lung cancer based on recent data presented at ASCO 2021.

Drs Chaitali Nangia and Sandip P. Patel debate between best treatment approaches for patients with non–small cell lung cancer in the perioperative setting.

Experts in cancer care review the phase 3 AENEAS trial with aumolertinib and the cost-effectiveness.

Mark Socinski, MD, Gilberto Lopes, MD, and Jack West, MD, provide an overview of the role of EGFR-targeted TKIs in NSCLC and the costs.

Recommendations for EGFR testing in patients with non–small cell lung cancer based on the wide heterogeneity of these mutations.

Mark A. Socinski, MD, highlights the targeted agents available to treat non–small cell lung cancer with EGFR mutations.

Recommendations for mitigating and managing common treatment-related adverse events associated with mobocertinib and other tyrosine kinase inhibitors.

Dr Roy S. Herbst comments on the utilization of biomarkers and information needed to help aid in treatment decisions about perioperative therapy for patients with resectable non–small cell lung cancer.

Dr Martin Dietrich comments on the IMpower010 trial of atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected non–small cell lung cancer.

Jack West, MD, and Gilberto Lopes, MD, share their thoughts on the impact of payers when dealing with the cost of treatments.

Gilberto Lopes, MD, and Afsaneh Barzi, MD, PhD, discuss personalized treatment plans based on innovative therapies and affordability.

Commentary on the use of EGFR tyrosine kinase inhibitors and their efficacy on non–small cell lung cancer brain metastases.

Potential implications for treating patients with metastatic non–small cell lung cancers with EGFR exon 20 insertion mutations with mobocertinib, based on the EXCLAIM cohort.